PRO118 WHAT IS THE IMPACT OF ORPHAN DRUG RE-ASSESSMENTS IN GERMANY ON THEIR ADDITIONAL BENEFIT AND PRICE?

Abstract

Authors

A. Pownell

Full Text Cite This Article
Back to Volume 22, Supplemental S3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×